Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term placebo-controlled trial. Found 11 abstracts

Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA. Prevention and Treatment of Cancer-Related Infections. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1412-45.   PMCID: not NIH funded
Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG. Antiemesis Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2012 Apr;10(4):456-85.   PMCID: not NIH funded
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):628-+.   PMCID: not NIH funded
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network. 2010 Aug;8(8):904-31.   PMCID: not NIH funded
Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1331-9.   PMCID: not NIH funded
Crawford J, Kosmidis PA, Hirsch FR, Langer CJ. Targeting anemia in patients with lung cancer. JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):716-25.
Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward. CLINICAL CANCER RESEARCH. 2006 Jun;12(12):3661-97.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004 Jan;67 (5-6):390-6.
Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomedicine & Pharmacotherapy. 2002 Jul;56(5):215-22.
Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarano F, Babb JS, Mannon LJ, Kolson DL, Cohen JA. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS - Quantitative MR assessment. Neurology. 2000 Feb 22;54(4):813-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term placebo-controlled trial

placebo-controlled trial double-blind quality-of-life NCCN Clinical Practice Guidelines phase-iii trial NCCN Guidelines chemotherapy therapy randomized controlled-trial bone-marrow-transplantation breast-cancer patients receiving chemotherapy mastectomy epoetin-alpha status scale score metoclopramide plus dexamethasone in-situ hybridization prostaglandins pneumocystis-carinii-pneumonia herpes-simplex-virus first-line therapy cisplatin nonplatinum chemotherapy resonance progressive multifocal darbepoetin-alpha omega-3 PUFA sentinel-node biopsy stem-cell fuzzy-connectedness 1977 tbals dw-annals of internal medicine-v87-p552 2nd primary tumors nonsteroidal antiinflammatory drug docosahexaenoic acid cell lung-cancer hodgkins-disease survivors lung cancer activity hemoglobin metaanalysis breast cancer chemotherapy-induced versus-host-disease screening fatigue treatable contributing pain high-dose cisplatin lobular carcinoma in situ disability acupuncture-point stimulation bone marrow transplantation methylphenidate factors to fatigue kidney-disease phase-iii 1984 rson sl-annals of internal medicine-v100-p345 controlled-trial skin-sparing mastectomy MR upper-aerodigestive-tract 1993 evallier b-british journal of cancer-v68-p176 growth-factor receptor growth-factor-receptor 1990 mulder phm-annals of internal medicine-v113-p834 epoetin alfa adjuvant therapy surrogate end-points endocrine therapy cognitive-behavioral therapy quantification blood-pressure glatiramer acetate invasive pulmonary aspergillosis erythropoietin relapsing-remitting MS adverse drug events multicenter 1990 evallier b-european journal of cancer-v26-ps33 receptor antagonists randomized-trial stem-cell transplantation 1994 lcott ja-journal of clinical oncology-v12-p107 community oncology depression enhancing lesions cancer transfusion requirements high-grade dysplasia activated protein-kinase volume measurement 1994 entice hg-lancet-v343-p749 chronic red-cell carcinoma 1988 lcott ja-archives of internal medicine-v148-p2561 5-hydroxytryptamine-3 chronic hepatitis-c breast chemotherapy-induced nausea leukoencephalopathy blood-product support surgical adjuvant receiving l-carnitine supplementation lung carcinoma cost analysis-secondary bone neoplasms-retrospective study cancer-chemotherapy intervention magnetic- fish-oil treatment receptor antagonist cyclophosphamide cyclooxygenases randomized spontaneously hypertensive rats ductal carcinoma in situ anemia patient-level data antiemesis nonhemolytic transfusion reactions Oncology zoledronic acid expanded disability relaxation breathing exercise disease- chronic lymphocytic-leukemia erythropoiesis-stimulating agents hepatitis-b-virus and vomiting 1994 bbia v-cancer-v74-p1945 radiation therapy surgical adjuvant breast multiple-sclerosis NK-1 dietary eicosapentaenoic acid coronary heart-disease aplasia prostate-cancer fatigue assessment transplantation serial moderately-emetogenic chemotherapy multiple-day chemotherapy 1992 lcott ja-journal of clinical oncology-v10-p316 alpha-linolenic acid cardiovascular breast-conserving therapy 5-HT3-receptor antagonists pamidronate
Last updated on Wednesday, August 12, 2020